Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

DiagnosTear Achieves Major Scientific Milestone with Publication of TeaRx(TM) Clinical Study in Current Eye Research Journal

DiagnosTear’s TeaRx Validation Fails to Halt 65% Decline as CLARIFY Royalties Weigh on Near-Term Upside

By The Northwire Desk — AI Analysis Jun 05, 2026 · 08:31 DTR · 0.3 DiagnosTear Technologies Inc.
Executive Summary
  • On June 5, 2026, DiagnosTear announced the publication of a clinical manuscript in Current Eye Research validating its TeaRx™ point-of-care platform for Dry Eye Disease (DED).
  • The study evaluated ~500 DED patients and 100 healthy controls, demonstrating diagnostic performance, severity stratification, and a high negative predictive value for predicting responsiveness to Cyclosporine A therapy.
  • The publication follows a November 2025 collaboration with the Brien Holden Eye Research Centre at LV Prasad Eye Institute (LVPEI) to clinically validate TeaRx.
  • On May 12, 2026, the company secured exclusive global rights to the CLARIFY eye imaging platform for needle-free blood diagnostics via a definitive licensing agreement with Sheba Impact and Ramot.
  • Historical progression shows a steady build-up of clinical and commercial partnerships: regulatory approvals for TeaRx Red Eye in France (Feb 2026), LOIs for UK (Hanson Medical) and India (Renovate Biologicals) market entry, and a Frankfurt Stock Exchange listing (Oct 2025).
  • The company raised $925,000 via a non-brokered private placement in November 2025 at $0.50 per unit, issuing warrants exercisable at $1.00 until May 2027.
Material Impact
  • The June 5 publication is a routine validation step that confirms earlier clinical collaboration announcements. It does not introduce new commercial traction, regulatory clearance, or revenue recognition.
  • The CLARIFY licensing deal (May 12) is strategically significant but carries a 3-4% royalty structure on net sales and requires substantial clinical validation and regulatory approval before monetization.
  • The stock has declined approximately 65% from its December 2025 peak of $0.86 to the current $0.30, reflecting market skepticism regarding execution timelines, cash burn, and dilution risk.
  • The publication is incremental and expected. It does not alter the fundamental cash burn trajectory or immediately de-risk the commercialization pathway. The market has already priced in the clinical validation phase, resulting in a neutral-to-negative price reaction relative to the broader downtrend.
DTR · Price
Company Overview
  • DiagnosTear Technologies Inc. develops point-of-care diagnostic platforms for ophthalmology and general diagnostics.
  • Flagship product: TeaRx™, a CE-IVD approved rapid diagnostic system that analyzes tear fluid to diagnose, stratify, and predict treatment response for Dry Eye Disease and Red Eye conditions.
  • Pipeline expansion: CLARIFY, a non-invasive eye imaging platform utilizing optical imaging and AI to perform needle-free blood component analysis (hemoglobin, RBCs, WBCs).
  • Commercial strategy focuses on global distribution partnerships, Laboratory Developed Test (LDT) pathways, and point-of-care integration.
Read the original news release →

More from DiagnosTear Technologies Inc.

May 12, 2026 · 16:06

DiagnosTear Solidifies CLARIFY License, Moving from Dry-Eye to Blood Diagnostics, but Commercialization Cliff Looms

Other Feb 26, 2026 · 17:01

DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx(TM) Red Eye

Regulatory Feb 20, 2026 · 17:01

DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical

M&A / Property Jan 22, 2026 · 17:01

DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India

M&A / Property Dec 17, 2025 · 18:01

DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count

Other Dec 02, 2025 · 17:01

DiagnosTear Announces Clinical Study with AlyaTec to Advance Analytical Validation and FDA Submission Pathway of TeaRx(TM) Red Eye Diagnostic Test

Other